Idov-Safetm
Advanced Malignant Solid Tumor
Fudan UniversityEarly Phase 1Active
C
36/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 73/ 100
Competitive context
31 Active assets in the Advanced Malignant Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
mhb039a Minghui Pharmaceutical (Hangzhou) Ltd | Phase 2 | CCC |
mhb039a for Minghui Pharmaceutical (Hangzhou) Ltd | Phase 2 | CCC |
mhb036c for Minghui Pharmaceutical (Hangzhou) Ltd | Phase 2 | CCC |
Cannabis Oil National Cancer Institute, Naples | Phase 2 | CCC |
mhb036c Minghui Pharmaceutical (Hangzhou) Ltd | Phase 2 | CCC |
View all 38 →
Same molecule, other indications
Idov-Safetm is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →